ALNYLAM PHARMACEUTICALS, INC. ALNY revenue by segment, product and geography
In its fiscal year ending 2025-12-31, ALNYLAM PHARMACEUTICALS, INC. reported revenue across 9 products and services; the largest, Product, was $2.99B (+81.4% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Product$2.99Bshare n/a+81.4% yoy
- TTR$2.49Bshare n/a+103.3% yoy
- Amvuttra$2.31Bshare n/a+138.4% yoy
- Collaborations$553Mshare n/a+8.5% yoy
- Rare$500Mshare n/a+18.2% yoy
- GIVLAARI$308Mshare n/a+20.6% yoy
- OXLUMO$191Mshare n/a+14.6% yoy
- Royalty$174Mshare n/a+89.6% yoy
- +1 more member in the filing
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Product$1.17Bshare n/ano prior
- TTR$1.03Bshare n/ano prior
- Amvuttra$1.01Bshare n/ano prior
- Rare$142Mshare n/ano prior
- GIVLAARI$89.8Mshare n/ano prior
- Royalty$71.7Mshare n/ano prior
- +3 more members in the filing
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.